

Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set

Eun Sung Park¹, Rosalia Rabinovsky⁵, Mark Carey¹, Bryan T. Hennessy^{1,2}, Roshan Agarwal¹, Wenbin Liu³, Zhenlin Ju³, Wanleng Deng⁴, Yiling Lu¹, Hyun Goo Woo⁶, Sang-Bae Kim¹, Jae-Ho Cheong¹, Levi A. Garraway⁵, John N. Weinstein^{1,3}, Gordon B. Mills¹, Ju-Seog Lee¹, and Michael A. Davies^{1,4}

Abstract

Aberrations in oncogenes and tumor suppressors frequently affect the activity of critical signal transduction pathways. To analyze systematically the relationship between the activation status of protein networks and other characteristics of cancer cells, we did reverse phase protein array (RPPA) profiling of the NCI60 cell lines for total protein expression and activation-specific markers of critical signaling pathways. To extend the scope of the study, we merged those data with previously published RPPA results for the NCI60. Integrative analysis of the expanded RPPA data set revealed five major clusters of cell lines and five principal proteomic signatures. Comparison of mutations in the NCI60 cell lines with patterns of protein expression showed significant associations for PTEN, PIK3CA, BRAF, and APC mutations with proteomic clusters. PIK3CA and PTEN mutation enrichment were not cell lineage-specific but were associated with dominant yet distinct groups of proteins. The five RPPA-defined clusters were strongly associated with sensitivity to standard anticancer agents. RPPA analysis identified 27 protein features significantly associated with sensitivity to paclitaxel. The functional status of those proteins was interrogated in a paclitaxel whole genome small interfering RNA (siRNA) library synthetic lethality screen and confirmed the predicted associations with drug sensitivity. These studies expand our understanding of the activation status of protein networks in the NCI60 cancer cell lines, demonstrate the importance of the direct study of protein expression and activation, and provide a basis for further studies integrating the information with other molecular and pharmacological characteristics of cancer. *Mol Cancer Ther*; 9(2); 257–67. ©2010 AACR.

Introduction

The NCI60 cell line collection is the most extensively characterized panel of cancer cell lines in existence. It consists of 60 human cancer cell lines derived from nine different tumor types, including leukemia (LN), colon (CO), lung [non-small cell lung cancer (NSCLC)], central nervous system (CNS), renal (REN), melanoma (ME), ovarian (OVR), breast (BR), and prostate (PRO; ref. 1).

In part because of the extensive pharmacological characterization of NCI60, they have frequently been used as test samples for emerging technologies and methods of analysis (2–8). Global gene expression patterns and alterations of DNA copy numbers in the NCI60 collection have been assessed by a number of microarray-based technologies, and the resulting data sets have been pooled and analyzed together with pharmacological characteristics of the cell lines, providing a comprehensive interaction map between pharmacological and genetic characteristics of the cells (9–11).

Although those studies have yielded much useful information, there is a strong rationale for complementing them with a direct assessment of the expression and activation of proteins involved in critical signal transduction pathways. During the progression of cancer, many signaling proteins are activated through genetic, epigenetic, and post-translational events. Approaches based on gene expression signatures have been used to interrogate gain-of-function or loss-of-function events during tumor progression (12, 13), but such analyses cannot assess translational regulation. Indeed, previous studies have shown frequent and marked discordance between mRNA expression levels and protein levels in tumors and cell lines (14–17). Moreover, kinase signaling pathways are generally regulated by post-translational modifications,

Authors' Affiliations: ¹Department of Systems Biology, ²Department of Gynecologic Medical Oncology, ³Department of Bioinformatics and Computational Biology, ⁴Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; ⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; and ⁶Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Note: Supplementary material for this article is available at Molecular Cancer Therapeutics Online (<http://mct.aacrjournals.org/>).

Corresponding Author: Michael A. Davies, Department of Melanoma Medical Oncology and Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0904, Houston, TX 77030. Phone: 713-563-5270; Fax: 713-563-3424. E-mail: mdavies@mdanderson.org

doi: 10.1158/1535-7163.MCT-09-0743

©2010 American Association for Cancer Research.

particularly phosphorylation events. Direct examination of the phosphorylated and unphosphorylated forms of signaling proteins should improve our understanding of the molecular and pharmacologic characteristics of the NCI60 cell lines.

The reverse phase protein array (RPPA) is a powerful technology that provides quantitative measurement of protein expression and activation. Previously RPPA was used to profile the expression of 94 proteins in the NCI60 cell line collection (14, 18). Although that study provided a number of interesting findings, insight into the role of signaling networks was critically limited by the lack of antibodies that recognize activation-specific modifications of proteins. We have developed RPPA assays to assess post-translational modifications that reflect the activation status of many proteins involved in kinase signaling (19–22). Recently we used this technique to measure the levels of phosphorylated AKT (P-AKT) in the NCI60 cell lines, and found an unexpected difference in P-AKT levels in cell lines with PTEN loss as compared with those with PIK3CA mutations (22). Here we report the RPPA analysis of the NCI60 for an expanded panel of antibodies, including activation-specific markers of other signaling pathways and additional markers related to PI3K-AKT signaling. We merged these results with the existing RPPA data of the NCI60, and demonstrate a relatively high degree of reproducibility and correlation of overlapping antibodies between the data sets. The integrated RPPA data set was used to assess the association of tumor type with protein expression and activation, extending previous studies that did not include phospho-proteins (14, 18). We also did the first systematic evaluation of protein features associated with the oncogenic mutations present in the NCI60 (23). Finally, we did a pilot analysis to identify proteins that correlate with sensitivity to standard anticancer agents. The functional significance of proteins associated with taxol sensitivity was assessed by reviewing results of a paclitaxel whole-genome small interfering RNA (siRNA) synthetic lethality screen, and validated the predictive nature of these associations.

Materials and Methods

Reverse Phase Protein Array Studies

Two independent data sets of RPPA data were generated. An initial analysis (MDA_Pilot) was done by extracting proteins from cell pellets that were generated and provided by the National Cancer Institute (NCI). A subsequent analysis (MDA_CLSS) was done using viable cells obtained from the NCI and that were grown in our laboratory. Cells were maintained in RPMI 1640 supplemented with 5% fetal bovine serum at 37°C in a humidified 5% CO₂ atmosphere, and proteins were harvested when the cells reached ~70% confluence. These cells, and the cell pellets provided by the NCI, were lysed with buffer containing 1% Triton X-100, 50 mM Hepes pH 7.4,

150 mM NaCl, 1.5 mM MgCl₂, 1 mM EGTA, 100 mM NaF, 10 mM NaPPi, 10% glycerol, 1 mM Na₃VO₄, and Complete Protease Inhibitor Cocktail (Roche Diagnostics). Protein supernatants were isolated using standard methods (22), and protein concentration was determined by BCA assay (Pierce). Samples were diluted to a uniform protein concentration, and then they were denatured in 1% SDS for 10 minutes at 95°C. Samples were stored at –80°C until use. RPPA analysis was done as described previously (20–22). A logarithmic value reflecting the relative amount of each protein in each sample was generated for analyses. MDA_Pilot RPPA analysis was done using a total of 34 antibodies, and the MDA_CLSS analysis used 99 antibodies (Supplementary Table S1). The RPPA data set “NCI” was previously reported (14), and the publicly available data were downloaded from the NCI Developmental Therapeutics Program website.⁷ Each of the three RPPA data sets was independently normalized and mean-centered. The data sets were then merged into a single data set for subsequent analyses.

Statistical Analysis

Hierarchical cluster analysis was done using Cluster and Treeview.⁸ The reproducibility and correlation of results were tested by calculating Pearson Correlation coefficients. The associations between protein features and mutation status within cell line clusters were determined by χ^2 and Fisher's exact testing. Associations with drug sensitivity were assessed using the GI50 data for the NCI60 cell lines.⁹ Analyses of statistical associations between drug sensitivity and RPPA clusters were done by one-way ANOVA. Proteins significantly correlated with paclitaxel sensitivity were selected based on Pearson Correlation Coefficients ($P < 0.05$ by the t -statistic). All statistical analyses were done in the R language environment.¹⁰

Results

Integration and Analysis of RPPA Data Sets

Two new RPPA data sets for the NCI60 cell line set were generated. “MDA_PILOT” RPPA analysis was done using cell lysates generated from cell pellets provided by the NCI Developmental Therapeutics Program. That study included measurement of 34 protein features (Supplementary Table S1). A second study, “MDA_CLSS,” was done using cell lysates generated by independently growing the NCI60 cell lines in our laboratory using tissue culture conditions recommended by the NCI, with lysis of cells done directly on tissue culture plates. The

⁷ <http://www.dtp.nci.nih.gov>

⁸ <http://rana.lbl.gov/EigenSoftware.htm>

⁹ <http://www.dtp.nci.nih.gov>

¹⁰ <http://www.r-project.com>

MDA_CLSS analysis included 99 protein features, 26 of which overlapped with those in the MDA_Pilot (Supplementary Table S1; Supplementary Fig. S1A). A comparison of the two RPPA analyses showed that 20 out of 26 (76.9%) of the shared proteins had statistically significant, positive correlations (Supplementary Fig. S1B). Because those results supported the feasibility of merging independent RPPA data sets, and in order to maximize the strength of the proteomic analysis of the NCI60, the two data sets were integrated with previously published RPPA data on the NCI60 for 94 proteins.¹¹ Each data set was individually normalized and mean-centered prior to merging.

We first compared results for the three independent RPPA data sets. Five proteins (CTNNB1, CDH1, ESR1, MAPK1, and PRKCA) were common to all three sets (Supplementary Fig. S1C). Despite the many possible sources of variability and systematic differences, the results for CTNNB1 and CDH1 showed remarkably high concordance among all the three independent sets. For example, Pearson correlation coefficients for CTNNB1 expression levels were 0.92 (NCI versus MDA_PILOT, $P < 0.00001$), 0.86 (NCI versus MDA_CLSS, $P < 0.00001$), and 0.84 (MDA_PILOT versus MDA_CLSS, $P < 0.00001$). The direct interaction of those proteins is well-established (24), and the correlation of protein expression levels is consistent with previous studies that showed that loss of CDH1 results in decreased levels of CTNNB (25). The results for MAPK1 showed the weakest correlation between NCI data and MDA_PILOT data ($r = 0.16$, $P = 0.22$), but, the correlation between MAPK1 levels in the different sets was higher than those between MAPK1 and the other shared protein features (Supplementary Fig. S1C). The correlation of ESR1 and PRKCA expression between the two M.D. Anderson data sets was very high (PRKCA: $r = 0.917$, $P < 0.00001$; ESR1: $r = 0.93$, $P < 0.00001$), but there was only moderate correlation of the M.D. Anderson sets with NCI data (PRKCA: MDA_PILOT versus NCI $r = 0.23$, $P = 0.07$; MDA_CLSS versus NCI $r = 0.24$, $P = 0.06$; ESR1: MDA_PILOT versus NCI $r = 0.29$, $P = 0.02$; MDA_CLSS versus NCI $r = 0.26$, $P = 0.04$). The weak correlations might reflect any numbers of factors, such as differences in tissue culture conditions, methods for quantitating data, or specificity of antibodies used at the two institutions. For example, the antibody used to measure PRKCA in MDA_PILOT and MDA_CLSS recognizes an epitope that is reported to be specific to PRKCA, whereas the antibody used by the NCI is noted by its manufacturer to recognize PRKCB as well.¹² Despite those sometimes-weak correlations, measurements of a given protein in the three independent data sets were almost always as nearest neighbors in unsupervised hierarchical clustering analysis of the shared proteins (Supplementary Fig. S1C). That observa-

tion supported the strategy of using the combined data from the three RPPA experiments to study the proteins associated with other features of the NCI60 cell lines.

Unsupervised hierarchical clustering of the integrated RPPA data representing 222 protein features encompassing 167 unique features revealed five distinct clusters of cell lines (Fig. 1). The clusters generally reflected the different tumor types in the NCI60 cell line set. Cluster 1 is mainly composed of brain tumor lines (CNS). The members of cluster 2 are mostly lung (NSCLC) and renal cell carcinomas (REN). Cluster 3 includes all of the colon (CO) cancer cell lines, as well as a few cell types from other lineages. Cluster 4 includes all of the leukemia (LK) cell lines. Cluster 5 is entirely composed of melanoma (ME), including MDA-MB-435. Although MDA-MB-435 was initially thought to be a breast cancer cell line, a variety of genotypic and phenotypic data confirm that it is melanoma in origin, a somewhat diverged version of M14 melanoma (6, 26, 27). Cluster 2 included four of seven ovarian cell lines, including OV-CAR8_ADR-RES, which had originally been thought to be a derivative of MCF7 breast cancer and then was renamed an agnostic NCI_ADR-RES by DTP. Microsatellite fingerprinting and other molecular analyses indicate that it is actually a drug-resistant derivative of OV-CAR8 (26). Breast (BR) lines were scattered throughout the clusters, suggesting phenotypic heterogeneity. Overall four tumor types (CNS, ME, LK, and CO) were significantly enriched within clusters, whereas the remaining five tumor types (BR, NSCLC, OVR, REN, and PRO) were not associated with particular clusters by χ^2 or Fisher's exact tests (Table 1).

We identified five groups of proteins ("A" to "E") that were up-regulated in the clusters of cell lines described above (Supplementary Fig. S2). The proteomic signature A, characteristic of melanoma, includes total protein levels of several components of the PI3K-AKT signaling network (PI3K.p110, AKT, FRAP1, GSK3), but does not include any activation-specific markers for this pathway. Signature A also includes total proteins in the MAPK signaling pathway (HRAS, MAPK1, MAP2K2), and an activation-specific marker (MEK1&2_pS217_S221). Signature B, which is leukemia-specific, includes proteins involved in cellular proliferation (MCM7, PCNA, GRB2, EIF4E, IRS1, HNRNPA1, c-MYC, c-MYC_pT58S62) and cell cycle progression (CDC2, CDK4, CDK7, CCNB1, CDKN1A), compatible with the high proliferative rates of leukemia cell lines. Signature C consists mainly of colon cancer lines and includes proteins involved in cell adhesion (CTNNB1, CDH1, CDH3). CDH1 (MDA_PILOT data) shows the most dramatic increase in expression in cluster C (97fold increase versus the other clusters). Signature D reflects proteins highly expressed in cell line cluster 2 with mixed cell lineages. Signature D includes a group of tightly correlated proteins: PRKCA, PRKCA_pS567, CAV1, C-JUN, EGFR, and TGM1. Finally, signature E is CNS-specific and reflects activation of the PI3K-AKT pathway. Many activation-specific proteins

¹¹ <http://www.dtp.nci.nih.gov>

¹² <http://www.bdbiosciences.ca>

forms in the pathway were expressed at high levels in the cluster (AKT_pS473, AKT_pT308, GSK3 α & β _pS21_S9, FOXO3A_pS318_S321, RPS6KB1_pS235_S236, RPS6KB1_pS240_S244).

Association of Mutations with Proteomic Signatures. Recently, the mutation status of 24 cancer-related genes was determined for all of the NCI60 cell lines and identified oncogenic mutations in 20 of the genes (23). To assess systematically the relationship between cancer-prevalent mutations and patterns of protein expression and activation, we measured the associations between those mutations and the proteomic signatures of the NCI60 (Fig. 2A). When contingency table analysis with five-group χ^2 and Fisher's exact tests was applied, the




Table 1. Association study of cancer cell types with integrated RPPA data of NCI 60 cell lines

Cell Type	χ^2 statistic	χ^2 P value	Fisher's exact test P value
Breast	3.024286	0.553769	0.794203
CNS*	19.48026	0.000632	0.000721
Colon*	15.00478	0.004691	0.008337
Leukemia*	23.21053	0.000115	0.000123
Lung	4.386675	0.356197	0.442148
Melanoma*	24.31579	6.90E-05	7.34E-05
Ovary	5.485714	0.240988	0.356018
Prostate	5.114551	0.275744	0.648159
Renal	9.127127	0.057999	0.06333

NOTE: Five group χ^2 test and Fisher's exact test of cell types against RPPA-defined clusters were done.

*Cell types showing significant enrichment in specific clusters.

mutations in four genes (PTEN, BRAF, PIK3CA, APC) were significantly enriched, in particular, RPPA-derived clusters (Table 2). Mutations in BRAF were significantly enriched in cluster 5 (7 out of 8 cell lines, $P = 0.006$ by χ^2 test). Homozygous mutations of PTEN were most enriched in cluster 1 ($P = 0.048$ in Fisher's exact test). The presence of any mutation in PTEN was also enriched in cluster 1, but this was not statistically significant (6 out of 12 cell lines, $P = 0.136$ by χ^2 test). Mutation in PIK3CA was enriched in cluster 3 (6 out of 7 cell lines), although that trend did not reach statistical significance ($P = 0.103$ by χ^2 test). Similarly, mutations in APC, BRCA2, and SMAD4 were more abundant in cluster 3, but their enrichment did not reach statistical significance. Because the five clusters of cell lines identified by protein features partly reflected tumor types in the NCI60, we carried out nine-group χ^2 and Fisher's exact tests to assess the association between mutation status and cancer cell type (Supplementary Table S2). As predicted by previous studies, mutation of BRAF was significantly enriched in the melanoma cell lines ($P = 0.010$ by χ^2 test), whereas mutations in APC and BRCA2 were significantly

Figure 1. RPPA analysis of the NCI 60 RPPA cell lines and tumor types. Unsupervised hierarchical clustering analysis of the integrated proteomic data representing 222 protein features (167 unique features) from three independent NCI60 RPPA data sets is shown. The RPPA data sets were independently normalized and mean centered before integration. Categorization of the cells into one of five clusters is indicated by CLUSTER below the cell line names. The cancer cell type from which each cell line originated is indicated by CELL-TYPE below the color-coded label for CLUSTER. The groups of proteins that demonstrate increased expression characteristic of the different cell line clusters are indicated to the left (Signature A to E). The RPPA data set source for each protein is indicated to the right of the heat map. Proteins assessed in more than one data set are also indicated (Same Antibody). Labels for all cell lines in each cluster are included in Figure 2; labels for all proteins are included in Supplementary Fig. S2.

Table 2. Association study of mutation status with integrated RPPA data of NCI 60 cell lines

Mutation	Total		Homozygous	
	χ^2 P value	Fisher's exact test P value	χ^2 P value	Fisher's exact test P value
P53	0.927015	0.935214	0.555924	0.575416
P16	0.450216	0.427948	0.250227	0.230189
RB	0.343613	0.441297	0.353376	0.417028
PTEN*	0.135962	0.109034	0.059305	0.047797
PIK3CA	0.103316	0.198385	NaN	1
LKB1	0.394828	0.519535	0.754997	0.913696
APC*	0.028054	0.058023	0.253053	0.634973
SMAD4	0.102952	0.173347	0.592418	1
VHL	0.696682	0.860656	0.696682	0.860656
RAS	0.240045	0.306594	0.665184	0.808537
B-RAF*	0.006084	0.01228	0.032172	0.039891
FLT3	0.217584	0.283333	NaN	1
BRCA1	0.592418	1	NaN	1
BRCA2	0.102952	0.173347	NaN	1
HER2	0.293537	0.636066	NaN	1
EGFR	0.293537	0.119672	0.217584	0.283333
PDGFR-a	0.217584	0.283333	NaN	1
B-CATENIN	0.451529	0.483333	NaN	1

NOTE: Five group χ^2 test and Fisher's exact test of mutation status against RPPA-defined clusters were done.

*Mutations showing significant enrichment in specific clusters.

mutations. Homozygous mutations in PTEN were significantly associated with cluster 1 ($P = 0.024$, χ^2 test; $P = 0.016$, Fisher's exact test), whereas cluster 2 was notable for a lack of mutation in PTEN ($P = 0.095$, by χ^2 test; Supplementary Tables S3 and S4). Mutations in PIK3CA ($P = 0.039$, χ^2 test; $P = 0.023$, Fisher's exact test), APC ($P = 0.005$; $P = 0.003$), BRCA2 ($P = 0.034$; $P = 0.022$), and SMAD4 ($P = 0.034$; $P = 0.022$) were enriched in cluster 3. Cluster 4 was not associated with any mutation set, probably because leukemias are frequently characterized by chromosomal rearrangements of oncogenes rather than missense mutations. Mutations in BRAF were significantly enriched in cluster 5 ($P = 0.001$, χ^2 ; $P = 0.001$, Fisher's exact test), consistent with the high prevalence of that mutation in melanoma.

The opposing associations of two clusters (clusters 1 and 2) with mutation in PTEN are intriguing. The clusters have similar proteomic signatures, as shown by their proximity in the unsupervised hierarchical clustering (Fig. 1). To identify protein features that distinguish cluster 1 and cluster 2, we carried out two-sample t tests and found that expression of six protein features (KRT18, KRT19, PTEN [MDA PILOT], PTEN [MDA CLSS], MGMT, TGM1) and phosphorylation of six protein features (AKT_pT308 [MDA_CLSS], AKT_pS473 [MDA_CLSS], AKT_pS473 [MDA_PILOT], MAPK14_pT180, Y182, RPS6KA1_pT389_S363, TSC2_pT1462) were significantly different ($P < 0.001$; Supplementary Fig. S3). PTEN expression was significantly higher (9.4fold and 8.6fold) in cluster 2, whereas phosphorylation of AKT

was significantly higher in cluster 1 (AKT_pS473: 4.95fold, AKT_pT308: 3.675fold). Although PTEN mutations were enriched in cluster 1, approximately 50% of the cell lines in that cluster do not harbor PTEN mutations and show normal PTEN expression. Thus, other genetic events are also sufficient to result in the observed pattern of protein expression, and/or contribute to the pattern of protein expression observed in the PTEN-null cell lines in the cluster.

Protein Signatures, Mutation Status, and Drug Sensitivity. We next investigated the relationship between proteomic profiles of the NCI60 cell lines and their sensitivity to anticancer agents. Analysis of the GI50 values for the NCI60 cell lines for a set of commonly used agents showed marked differences in average sensitivity among the five clusters of cell lines (Fig. 2A; Supplementary Fig. S4). Cluster 1, which is characterized by increased levels of activation-specific markers in the PI3K-AKT pathway, showed high sensitivity to rapamycin, an inhibitor of mTOR. In contrast, cluster 5, which is characterized by expression of total, but not activation-specific markers in the PI3K-AKT pathway, was less sensitive to rapamycin. Cluster 2, which demonstrates similarity to cluster 1 by hierarchical clustering but lacks the signature of PI3K-AKT pathway activation, was also less sensitive to rapamycin. Cluster 2 is characterized by lower sensitivity to paclitaxel and doxorubicin in relation to other clusters. Cell lines in cluster 4 showed high sensitivity to most of the chemotherapeutic agents. Paclitaxel ($P = 0.0026$ by one-way ANOVA), carboplatin ($P = 0.0028$),

and cisplatin ($P = 0.0038$) showed the most significant differences in sensitivity of the cells as a function of cell cluster (Fig. 2B).

Figure 3A shows the variation in GI50 values for paclitaxel within each RPPA-defined cluster. Most of the cells in cluster 4 were highly sensitive to paclitaxel. Cluster 2 was least sensitive to paclitaxel but showed a very wide range of drug responses suggesting that other factors are responsible for the heterogeneity. Nine group one-way ANOVA analysis for estimation of the influence of cancer cell type on paclitaxel showed significant differences ($P = 0.0041$) implying that drug sensitivity differences are related in part to cell lineage differences. Three cell types, CNS, colon, and leukemia, showed the most sensitivity to paclitaxel, whereas renal cell carcinoma showed the least sensitivity (Supplementary Fig. S5). The melanomas, lung cancers, ovarian cancers, and renal cell carcinomas showed wide ranges of drug sensitivity, reflecting the apparent heterogeneity of those cell types.

Comparisons of RPPA data with GI50 values for paclitaxel across the cell lines identified 27 protein features significantly correlated by Pearson correlation coefficient ($P < 0.05$; Table 3). Two proteins (CCND1 and Phospho-P38 MAPK) showed significant Pearson correlations in two independent RPPA experiments; thus 25 unique features were identified. Expression of CCND1 showed the most negative correlation with paclitaxel sensitivity ($r = -0.452$, $P = 0.00033$). Levels of transglutaminase 2 (TGM2), lung-resistance related protein (MVP), clathrin adaptor protein 50 (AP2M1), annexin A2 (ANXA2), *n*-cadherin (CDH2), STAT1, and keratin 19 (KRT19) were also significantly correlated with resistance (Fig. 3B). Metastasis inhibition factor NM23 (NME1) showed the highest positive correlation with paclitaxel sensitivity ($r = 0.364$, $P = 0.00464$). MCM7, ADNP, GSK3, SMN1, and MYC expression levels also correlated positively with paclitaxel sensitivity. To assess the functional effects of those genes on paclitaxel sensitivity, we reviewed the results of a whole-genome siRNA synthetic lethality screen done with paclitaxel in a human lung cancer cell line (28). In that screen, the effect of each gene on paclitaxel sensitivity was assessed by determining the ratio of the cell viability score for the combination of gene knockdown in the presence and the absence of paclitaxel. A paclitaxel to carrier ratio less than 1 suggests that gene knockdown results in increased sensitivity to paclitaxel, and thus supports that gene is a mediator of paclitaxel resistance. Overall, the proteins significantly associated with resistance to paclitaxel by RPPA had a lower ratio of paclitaxel to carrier cell viability than the proteins associated with sensitivity ($P = 0.03$; Fig. 3C). Eleven of the 13 proteins that correlated with paclitaxel resistance by RPPA had a paclitaxel to carrier ratio <1 , and 5 of those proteins showed a statistically significant ($P < 0.05$) difference in growth in the presence of paclitaxel (Table 3). Among the proteins correlated with sensitivity to paclitaxel, only 5 of the 12 had a ratio <1 , and none showed statically significant difference in growth.

Assessment of the expression levels of the significantly correlated proteins across the NCI60 cell lines reflected the differences in paclitaxel sensitivity observed across the RPPA-based clusters (Fig. 3D). TGM2 and ANXA2 were highly expressed in cluster 2 (least sensitive to paclitaxel), whereas they were expressed at the lowest levels in cell lines in cluster 4 (most sensitive to paclitaxel). MYC, MCM7, and NME1 were expressed at the highest levels in cluster 4 (as part of RPPA signature B for cluster 4). We surmise that the differences in sensitivity to paclitaxel result in part from differences in protein signaling that are the cumulative outcomes of differences in cell type and mutation status.

Discussion

There is a great need to improve our understanding of the molecular characteristics and heterogeneity of cancer. The NCI60 is a powerful tool for such studies, due to the wealth of data publicly available about those cell lines (1–6). Although much is known about the DNA, RNA, and pharmacologic aspects of the lines, data on protein expression and activation is much more limited. Previous proteomic analyses of the NCI60 have yielded important information, including the marked lack of correlation between protein and mRNA expression levels for several families of proteins (14, 18). However, those studies did not include a direct assessment of the activation status of signaling pathways. We have extended the available body of data available on the NCI60 by performing RPPA analysis using activation-specific markers for several cell-signaling pathways. We have used those data in concert with other available proteomic data to extend our understanding of the patterns of protein expression and activation that characterize different tumor types, cancer-prevalent mutations, and drug sensitivities.

Comparison of the protein expression data from three independent RPPA studies of the NCI60 demonstrate that proteomic signatures are relatively robust and reproducible, even when generated in completely independent laboratories. Supporting the robustness of the proteomic analysis of a relatively small number of features, the RPPA-derived clusters of the NCI-60 cell lines largely recapitulate the results observed by whole genome mRNA profiling (6). That conclusion is most clearly indicated by assignment of the MDA MB 435 cell line to the melanoma cluster, as has been shown in a number of transcriptional profiling studies and microsatellite fingerprinting (6, 26). The addition of activation-specific markers provides further information about the distinctions between the groups of cell lines. For example, although clusters 1 and 2 are closely related by hierarchical cluster analysis, there are marked differences between the two clusters in the levels of activation-specific markers in the PI3K-AKT signaling pathway (Fig. 1; Supplementary Fig. S3). In contrast, the two clusters did not differ significantly in total protein expression levels for the majority of the pathway components, such as AKT. In addition, cluster

5 was characterized by increased total-protein levels of several components of the PI3K-AKT pathway, but it did not feature increased activation-specific pathway markers. The functional significance of that additional

information is reflected in an increased sensitivity to rapamycin, an inhibitor of signaling downstream of AKT, in cluster 1 in comparison with clusters 2 and 5. Thus, the inclusion of activation-specific markers provides




Table 3. Proteins that correlate with paclitaxel sensitivity

Protein	RPPA Category	RPPA Versus -Log GI50 <i>r</i> Value	RPPA Versus -Log GI50 <i>P</i> value	Gene Symbol	siRNA Average Viability (Paclitaxel)	siRNA Average Deviation (Paclitaxel)	siRNA Average Viability (Carrier)	siRNA Average Deviation (Carrier)	siRNA Ratio (Paclitaxel/Carrier)	siRNA Versus Carrier <i>P</i> value
CCND1	Resistant	-0.452	<0.001	CCND1	0.651	0.044	0.839	0.026	0.776	0.023
TGM2	Resistant	-0.411	0.001	TGM2	0.678	0.007	0.752	0.016	0.902	0.007
MVP	Resistant	-0.370	0.004	MVP	0.688	0.035	0.783	0.022	0.878	0.0644
AP2M1	Resistant	-0.349	0.007	AP2M1	0.766	0.021	0.872	0.031	0.878	0.052
CDH2	Resistant	-0.345	0.007	CDH2	0.684	0.028	0.779	0.016	0.878	0.038
ANXA2	Resistant	-0.344	0.008	ANXA2	0.669	0.074	0.760	0.052	0.881	0.261
KRT19	Resistant	-0.328	0.011	KRT19	0.644	0.021	0.689	0.044	0.935	0.292
STAT1	Resistant	-0.326	0.012	STAT1	0.761	0.030	0.877	0.018	0.868	0.016
TRADD	Resistant	-0.298	0.022	TRADD	0.897	0.032	1.070	0.060	0.838	0.035
PGR	Resistant	-0.289	0.026	PGR	0.935	0.047	0.931	0.014	1.004	0.931
JAK1	Resistant	-0.265	0.042	JAK1	1.039	0.037	1.183	0.030	0.879	0.019
KRT18	Resistant	-0.260	0.047	KRT18	1.042	0.004	1.025	0.037	1.017	0.698
STAT6	Resistant	-0.260	0.046	STAT6	0.766	0.024	0.810	0.034	0.946	0.274
S6	Sensitive	0.28	0.032	RPS6	0.831	0.008	0.789	0.027	1.053	0.134
MYC;	Sensitive	0.288	0.027	MYC	0.710	0.032	0.814	0.046	0.873	0.086
MYCpT58	Sensitive	0.296	0.023							
P-MAPK	Sensitive	0.303	0.019	MAPK1	0.892	0.025	0.926	0.012	0.963	0.191
(P-MAPK)	Sensitive	0.303	0.019	MAPK3	0.869	0.039	0.814	0.023	1.068	0.191
GSK3 α/β	Sensitive	0.306	0.019	GSK3	1.116	0.063	1.140	0.049	0.979	0.714
(GSK3 α/β)	Sensitive	0.306	0.019	GSK3	1.152	0.080	1.099	0.054	1.048	0.531
P-JNK	Sensitive	0.309	0.017	MAPK8	1.079	0.047	0.986	0.016	1.095	0.078
SMN1	Sensitive	0.318	0.014	SMN1	0.596	0.287	0.825	0.042	0.722	0.369
ADNP	Sensitive	0.323	0.013	ADNP	1.081	0.053	1.053	0.041	1.027	0.627
P-P38	Sensitive	0.325	0.012	MAPK14	0.914	0.050	0.886	0.018	1.032	0.518
MCM7	Sensitive	0.351	0.006	MCM7	0.885	0.016	0.940	0.029	0.941	0.097
NME1	Sensitive	0.364	0.005	NME1	0.958	0.040	0.949	0.012	1.010	0.800
Median	Resistant	-0.328	0.011		0.761	0.030	0.839	0.030	0.879	0.052
Median	Sensitive	0.306	0.019		0.892	0.040	0.926	0.029	1.010	0.191

NOTE: For antibodies that recognize more than one protein (i.e., GSK3 α/β recognizes both GSK3 α and GSK3 β), the results for siRNA against each protein is presented. Both Total and Phospho MYC protein levels correlated with sensitivity to paclitaxel. For siRNAs that showed a significant difference ($P < 0.05$) for growth in the presence of paclitaxel as compared the carrier, the related proteins and *P* values presented in bold text.

insight into the functional differences between these otherwise closely-related groups of cells.

In this study we did the first systematic comparison of the oncogenic mutations in the NCI60 with their proteomic profiles. As described above, although clusters 1 and

2 share many protein features, only cluster 1 has a proteomic signature that includes elevated phospho-protein levels of several components of the PI3K-AKT pathway (AKT, TSC2, GSK3, S6, FOXO3A). Cluster 1 is highly enriched with PTEN mutations. Although activation of

Figure 3. Protein factors associated with paclitaxel responsiveness in the NCI60 panel. A, box-plot analysis of negative log10 GI50 values for paclitaxel in each RPPA-defined cluster. B, Pearson correlation coefficients for proteins significantly correlated with paclitaxel response across the NCI 60 cell lines (P values for the Pearson correlation < 0.05). Positive values indicate that high expression is associated with high sensitivity; negative values reflect association with paclitaxel resistance. C, effect of proteins significantly associated with paclitaxel sensitivity on relative growth of lung cancer cells in the presence of paclitaxel. The results of a previously published whole genome siRNA library \pm paclitaxel synthetic lethality screen (28) were reviewed. Y-axis, ratio of relative growth for cells in the presence of siRNA with paclitaxel to siRNA with vehicle. The dotted line indicates paclitaxel to carrier ratio of 1. The red bars indicate the median of each group. Filled triangle, significant difference ($P < 0.05$) for growth in the presence of paclitaxel versus carrier. D, expression of proteins significantly correlating with paclitaxel GI50 values in the NCI60. Cells are organized by the results of unsupervised hierarchical clustering of the RPPA data (Fig. 1). Heat maps show protein expression levels negatively (upper panel) and positively (lower panel) correlated with sensitivity. The RPPA cluster and cell type for each cell line are indicated. The $-\log_{10}$ GI50 value for paclitaxel for each cell line is presented above the heat map.

PI3K-AKT signaling is significantly associated with the mutation status of PTEN, it is not associated with the mutation status of PIK3CA (clusters 1 and 3). This observation is consistent with our previous analysis of a much smaller set of proteins, including phospho-AKT, in the NCI60 cell lines, as well as an analysis of an independent panel of breast cancer cell lines and clinical specimens (20, 22). Thus, the protein expression data and mutation status complement each other to provide understanding not available from either alone.

There is a great need for biomarkers to predict responsiveness to anticancer agents. A number of previous analyses have used the abundant pharmacologic data for the NCI60 cell lines to test associations between drug sensitivity and DNA copy numbers, DNA methylation, mRNA and miRNA expression, and oncogenic mutations (3, 29–32). We did a pilot analysis of the expanded RPPA protein expression data with drug sensitivity for a panel of 10 commonly used agents. In addition to the previously noted association of rapamycin sensitivity with increased expression of activation-specific markers in the PI3K-AKT pathway, we examined protein features associated with sensitivity to several commonly used cytotoxic agents. We identified 25 unique protein features significantly associated with sensitivity to paclitaxel. The correlations with sensitivity and resistance by RPPA matched functional results for the proteins in a published paclitaxel whole genome siRNA synthetic lethality screen (28). Those findings indicate the likely benefit of additional studies that expand the approach to the larger collection of agents for which sensitivity is known for the NCI60 cell lines. In addition, it will be important to integrate the proteomic data with other molecular char-

acteristics of the cell lines for such analyses, as has proved beneficial in multiple studies (17, 31–33).

In conclusion, this study again demonstrates the tremendous potential of the RPPA technology to provide information about the status of protein networks in cancer. Our analyses suggest that the reproducibility of the RPPA data are such that assimilating data from multiple sources is feasible, and that may help overcome the limitation of the relatively small number of markers that can be assessed in individual studies. The inclusion of phosphorylation-specific antibodies in our RPPA analysis improves the ability to assess protein networks functionally. However, many other functional aspects of protein networks remain to be assessed. The data here supports the hypothesis that such direct analyses of protein networks may improve our understanding of the underpinnings of cancer. When integrated with other available data, the information may lead to more effective therapeutic approaches.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

M.D. Anderson Cancer Center (MDACC) Melanoma Spore Development Grant (M.A. Davies). The M.D. Anderson Reverse Phase Protein Array Core Facility is supported by a National Cancer Institute (NCI) Cancer Center Support Grant (CA-16672).

Received 8/12/09; revised 11/24/09; accepted 12/8/09; published OnlineFirst 2/2/10.

References

- Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. *Nat Rev Cancer* 2006;6:813–23.
- Blower PE, Verducci JS, Lin S, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. *Mol Cancer Ther* 2007;6:1483–91.
- Bussey KJ, Chin K, Lababidi S, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. *Mol Cancer Ther* 2006;5:853–67.
- Ehrich M, Turner J, Gibbs P, et al. Cytosine methylation profiling of cancer cell lines. *Proc Natl Acad Sci U S A* 2008;105:4844–9.
- Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. *Cancer Res* 2007;67:2456–68.
- Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. *Nat Genet* 2000;24:227–35.
- Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. *Nat Genet* 2000;24:236–44.
- Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. *Science* 1997;275:343–9.
- Dan S, Tsunoda T, Kitahara O, et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. *Cancer Res* 2002;62:1139–47.
- Ring BZ, Chang S, Ring LW, Seitz RS, Ross DT. Gene expression patterns within cell lines are predictive of chemosensitivity. *BMC Genomics* 2008;9:74.
- Wallqvist A, Rabow AA, Shoemaker RH, Sausville EA, Covell DG. Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. *Mol Cancer Ther* 2002;1:311–20.
- Lee JS, Chu IS, Mikaelyan A, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. *Nat Genet* 2004;36:1306–11.
- Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nat Genet* 2005;37:48–55.
- Shankavaram UT, Reinhold WC, Nishizuka S, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integrative microarray study. *Mol Cancer Ther* 2007;6:820–32.
- Stevens EV, Nishizuka S, Antony S, et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. *Mol Cancer Ther* 2008;7:10–8.
- Tian Q, Stepaniants SB, Mao M, et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. *Mol Cell Proteomics* 2004;3:960–9.
- Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. *Cancer Cell* 2005;8:393–406.
- Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. *Proc Natl Acad Sci U S A* 2003;100:14229–34.
- Davies MA, Stemke-Hale K, Lin E, et al. Integrated molecular and

- clinical analysis of AKT activation in metastatic melanoma. *Clin Cancer Res* 2009;15:7538–46.
20. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. *Cancer Res* 2008;68:6084–91.
 21. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. *Mol Cancer Ther* 2006;5:2512–21.
 22. Vasudevan KM, Barbie DA, Davies MA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. *Cancer Cell* 2009;16:21–32.
 23. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. *Mol Cancer Ther* 2006;5:2606–12.
 24. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? *Oncogene* 2008;27:6920–9.
 25. Herzig M, Savarese F, Novatchkova M, Semb H, Christofori G. Tumor progression induced by the loss of E-cadherin independent of [beta]-catenin/Tcf-mediated Wnt signaling. *Oncogene* 2006;26:2290–8.
 26. Lorenzi PL, Reinhold WC, Varma S, et al. DNA fingerprinting of the NCI-60 cell line panel. *Mol Cancer Ther* 2009;8:713–24.
 27. Mikheev AM, Mikheeva SA, Rostomily R, Zarbl H. Dickkopf-1 activates cell death in MDA-MB435 melanoma cells. *Biochem Biophys Res Commun* 2007;352:675–80.
 28. Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. *Nature* 2007;446:815–9.
 29. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. *Proc Natl Acad Sci U S A* 2007;104:13086–91.
 30. Lorenzi PL, Llamas J, Gunsior M, et al. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. *Mol Cancer Ther* 2008;7:3123–8.
 31. Shen L, Kondo Y, Ahmed S, et al. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. *Cancer Res* 2007;67:11335–43.
 32. Staunton JE, Slonim DK, Collier HA, et al. Chemosensitivity prediction by transcriptional profiling. *Proc Natl Acad Sci U S A* 2001;98:10787–92.
 33. Ma Y, Ding Z, Qian Y, et al. An integrative genomic and proteomic approach to chemosensitivity prediction. *Int J Oncol* 2009;34:107–15.